GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GlaxoSmithKline plc (LSE: GSK) today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$13.00 per share in cash.
GSK's offer represents a premium of 81 percent to HGS's closing share price of US$7.17 on 18th April, the last trading day before HGS publicly disclosed GSK's private offer.
The closing of the tender offer is subject to the terms and conditions detailed in the offer document. The tender offer and withdrawal rights are scheduled to expire at 12:00 midnight New York City time on 7 June 2012 unless the offer is extended.
Lazard and Morgan Stanley are acting as financial advisors to GSK and Cleary Gottlieb Steen & Hamilton and Wachtell, Lipton, Rosen & Katz are providing legal advice.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Most Read News
- Big multiple sclerosis breakthrough
- Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"
- Fish oil supplements may help fight against Type 2 diabetes
- Vortioxetine, a new multimodal agent in development for the treatment of major depression
- Research offers promising new approach to treatment of lung cancer
- AstraZeneca to acquire Omthera Pharmaceuticals including NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio
- Amgen and Astellas announce Japan Alliance
Company Profiles and News
Showcase your Company Profile / News
Pharmaceutical Companies
News in Pictures
Be on top of World Pharma News!
Advertise with us - Download World Pharma News' Media Pack Read more
Abbott Launches New Psoriasisanswers.com Web site
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more
AstraZeneca Headquarters, London
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more
Site Roche Basel
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more
Gehry building, Novartis headquarters in Basel, Switzerland
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more
GSK Corporate HQ
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more
Sanofi-aventis Group head office
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more
Boehringer Ingelheim Center, Ingelheim, Germany
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more
Novo Nordisk's corporate headquarters in Bagsværd, Denmark
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more
Business & Industry News
- AstraZeneca selects location for new global R&D centre and corporate headquarters
- MedImmune, AstraZeneca's biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity
- FDA approves Amgen's XGEVA® (denosumab) for the treatment of giant cell tumor of bone
- Bristol-Myers Squibb and Simcere enter partnership to co-develop and co-commercialize Orencia® SC (abatacept) in China
- Pfizer obtains $2.15 billion settlement from Teva and Sun for infringement of Protonix® patent
- New four-strain influenza vaccine from Sanofi Pasteur now licensed by FDA
- AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio
Research & Development News
- Aspirin may fight cancer by slowing DNA damage
- Diabetes drug points the way to overcoming drug resistance in melanoma
- Investigation into safety of new diabetes drugs
- Big multiple sclerosis breakthrough
- Musculoskeletal conditions, injuries may be associated with statin use
- MyHealthAvatar Survey: Your Opinion Counts
- Double dose of antiviral drug offers no added benefit in severe influenza
Regulatory Affairs News
- FDA budget requests $4.7 billion
- FDA alerts health care providers of recall of anemia drug Omontys
- FDA approves Pomalyst for advanced multiple myeloma
- FDA approves Gleevec for children with acute lymphoblastic leukemia
- FDA approves new seasonal influenza vaccine made using novel technology
- FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation
- FDA expands use of Xarelto to treat, reduce recurrence of blood clots